Thanks to one of my LinkedIn contacts, I was introduced to a newly released “scorecard” that ranks pharmaceutical and biotechnology companies based on their precision medicine efforts. In essence, the organizations who made the cut are the ones moving precision medicine forward. They’re the ones focused on leveraging biomarkers to develop new therapies.
The factors taken into consideration to rank companies include:
- # of precision medicine drugs on the market
- % of clinical trials that leverage biomarkers
- % of employees who have a job title relating to precision medicine
While this may be somewhat of a rudimentary method of evaluating companies, to my knowledge, it’s the first ranking of its kind.
